Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,21987241,plasma concentrations,"Mean (SD) maraviroc plasma concentrations at pre-dose, 4 h post-dose and 6 h post-dose were 337 (74), 842 (174) and 485 (100) ng/mL and CSF concentrations at 4 h post-dose and 6 h post-dose were 7.5 (1.3) and 5.1 (1.2) ng/mL.",CNS effects of a CCR5 inhibitor in HIV-infected subjects: a pharmacokinetic and cerebral metabolite study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21987241/),[ng] / [ml],337,4253,DB04835,Maraviroc
,21987241,plasma concentrations,"Mean (SD) maraviroc plasma concentrations at pre-dose, 4 h post-dose and 6 h post-dose were 337 (74), 842 (174) and 485 (100) ng/mL and CSF concentrations at 4 h post-dose and 6 h post-dose were 7.5 (1.3) and 5.1 (1.2) ng/mL.",CNS effects of a CCR5 inhibitor in HIV-infected subjects: a pharmacokinetic and cerebral metabolite study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21987241/),[ng] / [ml],842,4254,DB04835,Maraviroc
,21987241,plasma concentrations,"Mean (SD) maraviroc plasma concentrations at pre-dose, 4 h post-dose and 6 h post-dose were 337 (74), 842 (174) and 485 (100) ng/mL and CSF concentrations at 4 h post-dose and 6 h post-dose were 7.5 (1.3) and 5.1 (1.2) ng/mL.",CNS effects of a CCR5 inhibitor in HIV-infected subjects: a pharmacokinetic and cerebral metabolite study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21987241/),[ng] / [ml],485,4255,DB04835,Maraviroc
,21987241,CSF,"Mean (SD) maraviroc plasma concentrations at pre-dose, 4 h post-dose and 6 h post-dose were 337 (74), 842 (174) and 485 (100) ng/mL and CSF concentrations at 4 h post-dose and 6 h post-dose were 7.5 (1.3) and 5.1 (1.2) ng/mL.",CNS effects of a CCR5 inhibitor in HIV-infected subjects: a pharmacokinetic and cerebral metabolite study. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21987241/),[ng] / [ml],7.5,4256,DB04835,Maraviroc
,21987241,CSF,"Mean (SD) maraviroc plasma concentrations at pre-dose, 4 h post-dose and 6 h post-dose were 337 (74), 842 (174) and 485 (100) ng/mL and CSF concentrations at 4 h post-dose and 6 h post-dose were 7.5 (1.3) and 5.1 (1.2) ng/mL.",CNS effects of a CCR5 inhibitor in HIV-infected subjects: a pharmacokinetic and cerebral metabolite study. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21987241/),[ng] / [ml],5.1,4257,DB04835,Maraviroc
,21987241,concentrations,"Mean (SD) maraviroc plasma concentrations at pre-dose, 4 h post-dose and 6 h post-dose were 337 (74), 842 (174) and 485 (100) ng/mL and CSF concentrations at 4 h post-dose and 6 h post-dose were 7.5 (1.3) and 5.1 (1.2) ng/mL.",CNS effects of a CCR5 inhibitor in HIV-infected subjects: a pharmacokinetic and cerebral metabolite study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21987241/),[ng] / [ml],7.5,4258,DB04835,Maraviroc
,21987241,concentrations,"Mean (SD) maraviroc plasma concentrations at pre-dose, 4 h post-dose and 6 h post-dose were 337 (74), 842 (174) and 485 (100) ng/mL and CSF concentrations at 4 h post-dose and 6 h post-dose were 7.5 (1.3) and 5.1 (1.2) ng/mL.",CNS effects of a CCR5 inhibitor in HIV-infected subjects: a pharmacokinetic and cerebral metabolite study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21987241/),[ng] / [ml],5.1,4259,DB04835,Maraviroc
,21987241,CSF : plasma ratio,The mean maraviroc CSF : plasma ratio (range) was 1.01% (0.57%-1.61%).,CNS effects of a CCR5 inhibitor in HIV-infected subjects: a pharmacokinetic and cerebral metabolite study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21987241/),%,1.01,4260,DB04835,Maraviroc
,29777772,oral bioavailability,"MVC has an oral bioavailability of approximately 33%, which is limited by poor permeability as well as affinity for CYP3A and several drug transporters.",Improving maraviroc oral bioavailability by formation of solid drug nanoparticles. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29777772/),%,33,17403,DB04835,Maraviroc
,29777772,z,"The lead formulation contained PVA and AOT excipients (MVCSDNPVA/AOT), and was demonstrated to be fully water-dispersible to release drug nanoparticles with z-average diameter of 728 nm and polydispersity index of 0.3.",Improving maraviroc oral bioavailability by formation of solid drug nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29777772/),,728,17404,DB04835,Maraviroc
,29777772,polydispersity index,"The lead formulation contained PVA and AOT excipients (MVCSDNPVA/AOT), and was demonstrated to be fully water-dispersible to release drug nanoparticles with z-average diameter of 728 nm and polydispersity index of 0.3.",Improving maraviroc oral bioavailability by formation of solid drug nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29777772/),,0.3,17405,DB04835,Maraviroc
,29777772,AUC,"In vitro and in vivo studies of MVCSDNPVA/AOT showed increased apparent permeability of MVC, compared to a conventional MVC preparation, with in vivo studies in rats showing a 2.5-fold increase in AUC (145.33 vs. 58.71 ng h ml-1).",Improving maraviroc oral bioavailability by formation of solid drug nanoparticles. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29777772/),[h·ng] / [ml],145.33,17406,DB04835,Maraviroc
,29777772,AUC,"In vitro and in vivo studies of MVCSDNPVA/AOT showed increased apparent permeability of MVC, compared to a conventional MVC preparation, with in vivo studies in rats showing a 2.5-fold increase in AUC (145.33 vs. 58.71 ng h ml-1).",Improving maraviroc oral bioavailability by formation of solid drug nanoparticles. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29777772/),[h·ng] / [ml],58.71,17407,DB04835,Maraviroc
,19133216,plasma T(max),"MVC is rapidly absorbed following oral administration, and plasma T(max) is achieved within 0.5- 4 hours after a 300 mg dose.","[Pharmacokinetics, interactions and mechanism of action of maraviroc]. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19133216/),h,0.5- 4,18466,DB04835,Maraviroc
,19133216,Renal clearance,Renal clearance is approximately 10-12 L/h.,"[Pharmacokinetics, interactions and mechanism of action of maraviroc]. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19133216/),[l] / [h],10-12,18467,DB04835,Maraviroc
,21502084,protein binding,"However, protein binding in SP ranged from 4% to 25%, resulting in protein-free concentrations >2-fold higher than BP.","Single and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative men. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21502084/),%,4,20486,DB04835,Maraviroc
,21502084,protein binding,"However, protein binding in SP ranged from 4% to 25%, resulting in protein-free concentrations >2-fold higher than BP.","Single and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative men. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21502084/),%,25,20487,DB04835,Maraviroc
,18333865,Renal clearance,Renal clearance of maraviroc plus placebo was 8.3 l h(-1) and 8.5 l h(-1) and was 7.8 l h(-1) for maraviroc plus cotrimoxazole and maraviroc plus tenofovir.,The effects of cotrimoxazole or tenofovir co-administration on the pharmacokinetics of maraviroc in healthy volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18333865/),[l] / [h],8.3,29250,DB04835,Maraviroc
,18333865,Renal clearance,Renal clearance of maraviroc plus placebo was 8.3 l h(-1) and 8.5 l h(-1) and was 7.8 l h(-1) for maraviroc plus cotrimoxazole and maraviroc plus tenofovir.,The effects of cotrimoxazole or tenofovir co-administration on the pharmacokinetics of maraviroc in healthy volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18333865/),[l] / [h],8.5,29251,DB04835,Maraviroc
,18333865,Renal clearance,Renal clearance of maraviroc plus placebo was 8.3 l h(-1) and 8.5 l h(-1) and was 7.8 l h(-1) for maraviroc plus cotrimoxazole and maraviroc plus tenofovir.,The effects of cotrimoxazole or tenofovir co-administration on the pharmacokinetics of maraviroc in healthy volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18333865/),[l] / [h],7.8,29252,DB04835,Maraviroc
,18333861,Renal clearance,Renal clearance is approximately 10-12 l h(-1) and appears unaffected by increasing maraviroc doses.,"Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18333861/),[l] / [h],10-12,29824,DB04835,Maraviroc
,19740392,Total clearance,Total clearance was 48 l h(-1) (2.2% SE).,Maraviroc modelling strategy: use of early phase 1 data to support a semi-mechanistic population pharmacokinetic model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19740392/),[l] / [h],48,44340,DB04835,Maraviroc
,19740392,hepatic blood flow,"The mass balance models calculated that 33.3% and 22.9% of 300 mg solution and 100 mg tablet doses, respectively, are systemically available, and first-pass metabolism extracts 62% of an absorbed dose, estimating a hepatic blood flow of 101 l h(-1).",Maraviroc modelling strategy: use of early phase 1 data to support a semi-mechanistic population pharmacokinetic model. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19740392/),[l] / [h],101,44341,DB04835,Maraviroc
,21508009,total plasma maximum concentration (C(max)),"The geometric mean (GM) raltegravir total plasma maximum concentration (C(max)), minimum concentration (C(min)) and area under the time-concentration curve from 0-12 h (AUC(0-12)) were 1068 ng/mL, 51.1 ng/mL and 4171 ng·h/mL, respectively.",Cell disposition of raltegravir and newer antiretrovirals in HIV-infected patients: high inter-individual variability in raltegravir cellular penetration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21508009/),[ng] / [ml],1068,48991,DB04835,Maraviroc
,21508009,minimum concentration (C(min)),"The geometric mean (GM) raltegravir total plasma maximum concentration (C(max)), minimum concentration (C(min)) and area under the time-concentration curve from 0-12 h (AUC(0-12)) were 1068 ng/mL, 51.1 ng/mL and 4171 ng·h/mL, respectively.",Cell disposition of raltegravir and newer antiretrovirals in HIV-infected patients: high inter-individual variability in raltegravir cellular penetration. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21508009/),[ng] / [ml],51.1,48992,DB04835,Maraviroc
,21508009,area under the time-concentration curve from 0-12 h (AUC(0-12)),"The geometric mean (GM) raltegravir total plasma maximum concentration (C(max)), minimum concentration (C(min)) and area under the time-concentration curve from 0-12 h (AUC(0-12)) were 1068 ng/mL, 51.1 ng/mL and 4171 ng·h/mL, respectively.",Cell disposition of raltegravir and newer antiretrovirals in HIV-infected patients: high inter-individual variability in raltegravir cellular penetration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21508009/),[h·ng] / [ml],4171,48993,DB04835,Maraviroc
,21508009,C(max),"GM raltegravir cellular C(max), C(min) and AUC(0-12) were 27.5 ng/mL, 2.9 ng/mL and 165 ng·h/mL, respectively.",Cell disposition of raltegravir and newer antiretrovirals in HIV-infected patients: high inter-individual variability in raltegravir cellular penetration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21508009/),[ng] / [ml],27.5,48994,DB04835,Maraviroc
,21508009,C(min),"GM raltegravir cellular C(max), C(min) and AUC(0-12) were 27.5 ng/mL, 2.9 ng/mL and 165 ng·h/mL, respectively.",Cell disposition of raltegravir and newer antiretrovirals in HIV-infected patients: high inter-individual variability in raltegravir cellular penetration. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21508009/),[ng] / [ml],2.9,48995,DB04835,Maraviroc
,21508009,AUC(0-12),"GM raltegravir cellular C(max), C(min) and AUC(0-12) were 27.5 ng/mL, 2.9 ng/mL and 165 ng·h/mL, respectively.",Cell disposition of raltegravir and newer antiretrovirals in HIV-infected patients: high inter-individual variability in raltegravir cellular penetration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21508009/),[h·ng] / [ml],165,48996,DB04835,Maraviroc
,21508009,AUC(cell)/AUC(tot) GM ratios,"The AUC(cell)/AUC(tot) GM ratios for raltegravir, darunavir and etravirine were 0.039, 0.14 and 1.55, respectively.",Cell disposition of raltegravir and newer antiretrovirals in HIV-infected patients: high inter-individual variability in raltegravir cellular penetration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21508009/),,0.039,48997,DB04835,Maraviroc
,21508009,AUC(cell)/AUC(tot) GM ratios,"The AUC(cell)/AUC(tot) GM ratios for raltegravir, darunavir and etravirine were 0.039, 0.14 and 1.55, respectively.",Cell disposition of raltegravir and newer antiretrovirals in HIV-infected patients: high inter-individual variability in raltegravir cellular penetration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21508009/),,0.14,48998,DB04835,Maraviroc
,21508009,AUC(cell)/AUC(tot) GM ratios,"The AUC(cell)/AUC(tot) GM ratios for raltegravir, darunavir and etravirine were 0.039, 0.14 and 1.55, respectively.",Cell disposition of raltegravir and newer antiretrovirals in HIV-infected patients: high inter-individual variability in raltegravir cellular penetration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21508009/),,1.55,48999,DB04835,Maraviroc
,18333867,total recovery,"The mean total recovery of dosed radioactivity was 96%, with the majority of radioactivity being recovered within 96 h postdose.","Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18333867/),%,96,59855,DB04835,Maraviroc
,18333867,total clearance,Approximately 23% of total clearance (44 l h(-1)) was accounted for by renal clearance (10.2 l h(-1)).,"Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18333867/),[l] / [h],44,59856,DB04835,Maraviroc
,18333867,renal clearance,Approximately 23% of total clearance (44 l h(-1)) was accounted for by renal clearance (10.2 l h(-1)).,"Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18333867/),[l] / [h],10.2,59857,DB04835,Maraviroc
,18333867,volume of distribution at steady state,Mean volume of distribution at steady state was 194 l.,"Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18333867/),l,194,59858,DB04835,Maraviroc
,18333867,Absolute bioavailability,"Absolute bioavailability of a 100-mg oral tablet dose, by comparison with a 30-mg i.v. dose, was calculated to be 23.1%.","Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18333867/),%,23.1,59859,DB04835,Maraviroc
,18333867,absolute bioavailability,The absolute bioavailability of 100 mg oral maraviroc is 23%.,"Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18333867/),%,23,59860,DB04835,Maraviroc
,18333869,CL,"Typical CL, V(c) and V(p) values for a 30-year-old non-Asian are 51.5 l h(-1), 132 l and 277 l, respectively.",A population pharmacokinetic meta-analysis of maraviroc in healthy volunteers and asymptomatic HIV-infected subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18333869/),[l] / [h],51.5,60438,DB04835,Maraviroc
,18333869,V(c),"Typical CL, V(c) and V(p) values for a 30-year-old non-Asian are 51.5 l h(-1), 132 l and 277 l, respectively.",A population pharmacokinetic meta-analysis of maraviroc in healthy volunteers and asymptomatic HIV-infected subjects. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18333869/),l,132,60439,DB04835,Maraviroc
,18333869,V(p),"Typical CL, V(c) and V(p) values for a 30-year-old non-Asian are 51.5 l h(-1), 132 l and 277 l, respectively.",A population pharmacokinetic meta-analysis of maraviroc in healthy volunteers and asymptomatic HIV-infected subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18333869/),l,277,60440,DB04835,Maraviroc
,18333869,bioavailability,"For the typical non-Asian subject, fasted bioavailability increased asymptotically with dose from 24% at 100 mg to 33% at 600 mg.",A population pharmacokinetic meta-analysis of maraviroc in healthy volunteers and asymptomatic HIV-infected subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18333869/),%,24,60441,DB04835,Maraviroc
,18333869,bioavailability,"For the typical non-Asian subject, fasted bioavailability increased asymptotically with dose from 24% at 100 mg to 33% at 600 mg.",A population pharmacokinetic meta-analysis of maraviroc in healthy volunteers and asymptomatic HIV-infected subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18333869/),%,33,60442,DB04835,Maraviroc
,27727157,IC90,"Concentrations from 4 to 72 hours were above intracellular (IC) IC90 in all compartments, range 15-8095 ng/mL.",Brief Report: Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27727157/),[ng] / [ml],15-8095,62614,DB04835,Maraviroc
,27727157,AUC0-72,Mean AUC0-72 compartment-to-plasma ratios were highest in the rectum (45-819) and urethra (144) compared with the female genital tract (1.6-4.8) and saliva (0.2).,Brief Report: Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27727157/),,45-819,62615,DB04835,Maraviroc
,27727157,AUC0-72,Mean AUC0-72 compartment-to-plasma ratios were highest in the rectum (45-819) and urethra (144) compared with the female genital tract (1.6-4.8) and saliva (0.2).,Brief Report: Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27727157/),,144,62616,DB04835,Maraviroc
,27727157,AUC0-72,Mean AUC0-72 compartment-to-plasma ratios were highest in the rectum (45-819) and urethra (144) compared with the female genital tract (1.6-4.8) and saliva (0.2).,Brief Report: Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27727157/),,0.2,62617,DB04835,Maraviroc
,27727157,compartment-to-plasma ratios,Mean AUC0-72 compartment-to-plasma ratios were highest in the rectum (45-819) and urethra (144) compared with the female genital tract (1.6-4.8) and saliva (0.2).,Brief Report: Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27727157/),,45-819,62618,DB04835,Maraviroc
,27727157,compartment-to-plasma ratios,Mean AUC0-72 compartment-to-plasma ratios were highest in the rectum (45-819) and urethra (144) compared with the female genital tract (1.6-4.8) and saliva (0.2).,Brief Report: Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27727157/),,144,62619,DB04835,Maraviroc
,27727157,compartment-to-plasma ratios,Mean AUC0-72 compartment-to-plasma ratios were highest in the rectum (45-819) and urethra (144) compared with the female genital tract (1.6-4.8) and saliva (0.2).,Brief Report: Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27727157/),,1.6-4.8,62620,DB04835,Maraviroc
,27727157,compartment-to-plasma ratios,Mean AUC0-72 compartment-to-plasma ratios were highest in the rectum (45-819) and urethra (144) compared with the female genital tract (1.6-4.8) and saliva (0.2).,Brief Report: Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27727157/),,0.2,62621,DB04835,Maraviroc
at,33252481,Cavg,Maraviroc exposure target was Cavg at least 75 ng/ml.,Pharmacokinetics and safety of maraviroc in neonates. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33252481/),[ng] / [ml],75,80326,DB04835,Maraviroc
,18333868,T(max),"The mean difference from placebo in machine-read QTcF at median T(max) for maraviroc 900 mg was 3.6 ms [90% confidence interval (CI) 1.5, 5.8].",Effect of single doses of maraviroc on the QT/QTc interval in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18333868/),ms,3.6,81193,DB04835,Maraviroc
,20371753,Ctrough,Raltegravir plasma Ctrough showed a large variability (range <0.020-2.47 microg/mL).,Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20371753/),[μg] / [ml],0.020-2.47,86234,DB04835,Maraviroc
,25117426,area under the plasma concentration-time curves from time 0 to infinity (AUC0-inf),"The median (interquartile range) maraviroc area under the plasma concentration-time curves from time 0 to infinity (AUC0-inf) were 2099 (1422-2568) ng⋅h/ml, 1761 (931-2640) ng⋅h/ml, and 1238 (1065-1407) ng⋅h/ml for the homozygous dysfunctional, heterozygous, and homozygous wild-type groups, respectively.",CYP3A5 genotype impacts maraviroc concentrations in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25117426/),[h·ng] / [ml],2099,100212,DB04835,Maraviroc
,25117426,area under the plasma concentration-time curves from time 0 to infinity (AUC0-inf),"The median (interquartile range) maraviroc area under the plasma concentration-time curves from time 0 to infinity (AUC0-inf) were 2099 (1422-2568) ng⋅h/ml, 1761 (931-2640) ng⋅h/ml, and 1238 (1065-1407) ng⋅h/ml for the homozygous dysfunctional, heterozygous, and homozygous wild-type groups, respectively.",CYP3A5 genotype impacts maraviroc concentrations in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25117426/),[h·ng] / [ml],1761,100213,DB04835,Maraviroc
,25117426,area under the plasma concentration-time curves from time 0 to infinity (AUC0-inf),"The median (interquartile range) maraviroc area under the plasma concentration-time curves from time 0 to infinity (AUC0-inf) were 2099 (1422-2568) ng⋅h/ml, 1761 (931-2640) ng⋅h/ml, and 1238 (1065-1407) ng⋅h/ml for the homozygous dysfunctional, heterozygous, and homozygous wild-type groups, respectively.",CYP3A5 genotype impacts maraviroc concentrations in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25117426/),[h·ng] / [ml],1238,100214,DB04835,Maraviroc
,27067321,steady-state drug levels,"Median, steady-state drug levels in vaginal tissue homogenate were as follows: for tenofovir (TFV; in vivo hydrolysis product of TDF), 7.3 × 10(2) ng g(-1) (interquartile range [IQR], 3.0 × 10(2), 4.0 × 10(3)); for TFV diphosphate (TFV-DP; active metabolite of TFV), 1.8 × 10(4) fmol g(-1) (IQR, 1.5 × 10(4), 4.8 × 10(4)); and for MVC, 8.2 × 10(2) ng g(-1) (IQR, 4.7 × 10(2), 2.0 × 10(3)).",Combination Pod-Intravaginal Ring Delivers Antiretroviral Agents for HIV Prophylaxis: Pharmacokinetic Evaluation in an Ovine Model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27067321/),[ng] / [g],7.3 ×,112918,DB04835,Maraviroc
,27067321,steady-state drug levels,"Median, steady-state drug levels in vaginal tissue homogenate were as follows: for tenofovir (TFV; in vivo hydrolysis product of TDF), 7.3 × 10(2) ng g(-1) (interquartile range [IQR], 3.0 × 10(2), 4.0 × 10(3)); for TFV diphosphate (TFV-DP; active metabolite of TFV), 1.8 × 10(4) fmol g(-1) (IQR, 1.5 × 10(4), 4.8 × 10(4)); and for MVC, 8.2 × 10(2) ng g(-1) (IQR, 4.7 × 10(2), 2.0 × 10(3)).",Combination Pod-Intravaginal Ring Delivers Antiretroviral Agents for HIV Prophylaxis: Pharmacokinetic Evaluation in an Ovine Model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27067321/),[fmol] / [g],1.8 × 10,112919,DB04835,Maraviroc
,27067321,steady-state drug levels,"Median, steady-state drug levels in vaginal tissue homogenate were as follows: for tenofovir (TFV; in vivo hydrolysis product of TDF), 7.3 × 10(2) ng g(-1) (interquartile range [IQR], 3.0 × 10(2), 4.0 × 10(3)); for TFV diphosphate (TFV-DP; active metabolite of TFV), 1.8 × 10(4) fmol g(-1) (IQR, 1.5 × 10(4), 4.8 × 10(4)); and for MVC, 8.2 × 10(2) ng g(-1) (IQR, 4.7 × 10(2), 2.0 × 10(3)).",Combination Pod-Intravaginal Ring Delivers Antiretroviral Agents for HIV Prophylaxis: Pharmacokinetic Evaluation in an Ovine Model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27067321/),[ng] / [g],8.2 × 10,112920,DB04835,Maraviroc
,24936594,steady-state drug levels,"Median steady-state drug levels in vaginal tissues in the TDF-FTC group were 30 μg g(-1) (tenofovir [TFV], in vivo hydrolysis product of TDF) and 500 μg g(-1) (FTC) and in the TDF-FTC-MVC group were 10 μg g(-1) (TFV), 150 μg g(-1) (FTC), and 20 μg g(-1) (MVC).",Pharmacokinetics and preliminary safety study of pod-intravaginal rings delivering antiretroviral combinations for HIV prophylaxis in a macaque model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24936594/),[μg] / [g],30,116910,DB04835,Maraviroc
,24936594,steady-state drug levels,"Median steady-state drug levels in vaginal tissues in the TDF-FTC group were 30 μg g(-1) (tenofovir [TFV], in vivo hydrolysis product of TDF) and 500 μg g(-1) (FTC) and in the TDF-FTC-MVC group were 10 μg g(-1) (TFV), 150 μg g(-1) (FTC), and 20 μg g(-1) (MVC).",Pharmacokinetics and preliminary safety study of pod-intravaginal rings delivering antiretroviral combinations for HIV prophylaxis in a macaque model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24936594/),[μg] / [g],10,116911,DB04835,Maraviroc
,24936594,steady-state drug levels,"Median steady-state drug levels in vaginal tissues in the TDF-FTC group were 30 μg g(-1) (tenofovir [TFV], in vivo hydrolysis product of TDF) and 500 μg g(-1) (FTC) and in the TDF-FTC-MVC group were 10 μg g(-1) (TFV), 150 μg g(-1) (FTC), and 20 μg g(-1) (MVC).",Pharmacokinetics and preliminary safety study of pod-intravaginal rings delivering antiretroviral combinations for HIV prophylaxis in a macaque model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24936594/),[μg] / [g],150,116912,DB04835,Maraviroc
,24936594,steady-state drug levels,"Median steady-state drug levels in vaginal tissues in the TDF-FTC group were 30 μg g(-1) (tenofovir [TFV], in vivo hydrolysis product of TDF) and 500 μg g(-1) (FTC) and in the TDF-FTC-MVC group were 10 μg g(-1) (TFV), 150 μg g(-1) (FTC), and 20 μg g(-1) (MVC).",Pharmacokinetics and preliminary safety study of pod-intravaginal rings delivering antiretroviral combinations for HIV prophylaxis in a macaque model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24936594/),[μg] / [g],20,116913,DB04835,Maraviroc
,15650075,log D(7,"The compound has physicochemical properties that are borderline for good pharmacokinetics, being moderately lipophilic (log D(7.4) 2.1) and basic (pK(a) 7.3), possessing a number of H-bonding functionalities, and with a molecular weight of 514.","Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15650075/),,2.1,118179,DB04835,Maraviroc
,24316669,IC₅₀,"Among synthesized target compounds, 16g (IC₅₀ = 25.73 nM) and 16i (IC₅₀ = 25.53 nM) showed equivalent inhibitory activity against CCR5 to that of the positive control maraviroc (IC₅₀ = 25.43 nM) in calcium mobilization assay.","Design, synthesis, and biological evaluation of novel piperidine-4-carboxamide derivatives as potent CCR5 inhibitors. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24316669/),nM,25.73,118508,DB04835,Maraviroc
,24316669,IC₅₀,"Among synthesized target compounds, 16g (IC₅₀ = 25.73 nM) and 16i (IC₅₀ = 25.53 nM) showed equivalent inhibitory activity against CCR5 to that of the positive control maraviroc (IC₅₀ = 25.43 nM) in calcium mobilization assay.","Design, synthesis, and biological evaluation of novel piperidine-4-carboxamide derivatives as potent CCR5 inhibitors. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24316669/),nM,25.53,118509,DB04835,Maraviroc
,24316669,IC₅₀,"Among synthesized target compounds, 16g (IC₅₀ = 25.73 nM) and 16i (IC₅₀ = 25.53 nM) showed equivalent inhibitory activity against CCR5 to that of the positive control maraviroc (IC₅₀ = 25.43 nM) in calcium mobilization assay.","Design, synthesis, and biological evaluation of novel piperidine-4-carboxamide derivatives as potent CCR5 inhibitors. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24316669/),nM,25.43,118510,DB04835,Maraviroc
,24316669,IC₅₀,"Two compounds, 16g and 16i, displayed antiviral activity with IC₅₀ values of 73.01 nM and 94.10 nM, respectively.","Design, synthesis, and biological evaluation of novel piperidine-4-carboxamide derivatives as potent CCR5 inhibitors. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24316669/),nM,73.01,118511,DB04835,Maraviroc
,24316669,IC₅₀,"Two compounds, 16g and 16i, displayed antiviral activity with IC₅₀ values of 73.01 nM and 94.10 nM, respectively.","Design, synthesis, and biological evaluation of novel piperidine-4-carboxamide derivatives as potent CCR5 inhibitors. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24316669/),nM,94.10,118512,DB04835,Maraviroc
<,29023357,concentrations (Cavg),Dose adjustment and pharmacokinetic reevaluation occurred if the average concentrations (Cavg) at Week 2 were <100 ng/mL (Stage 1-dose finding).,"Pharmacokinetics, Safety and Efficacy of Maraviroc in Treatment-experienced Pediatric Patients Infected With CCR5-Tropic HIV-1. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29023357/),[ng] / [ml],100,153541,DB04835,Maraviroc
≥,29023357,Cavg,Data from the Week 48 analysis demonstrated that 49/50 Stage 1 participants rolling over into Stage 2 (safety and efficacy) achieved Cavg ≥100 ng/mL.,"Pharmacokinetics, Safety and Efficacy of Maraviroc in Treatment-experienced Pediatric Patients Infected With CCR5-Tropic HIV-1. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29023357/),[ng] / [ml],100,153542,DB04835,Maraviroc
,21217360,Km,Maraviroc was identified as a substrate for OATP1B1 with a Km of 33.9 μmol/l.,Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21217360/),[μM] / [l],33.9,166067,DB04835,Maraviroc
,16251317,90% inhibitory concentration,"Maraviroc demonstrated potent antiviral activity against all CCR5-tropic HIV-1 viruses tested, including 43 primary isolates from various clades and diverse geographic origin (geometric mean 90% inhibitory concentration of 2.0 nM).","Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16251317/),nM,2.0,168005,DB04835,Maraviroc
>,16251317,50% inhibitory concentration,"Maraviroc has no detectable in vitro cytotoxicity and is highly selective for CCR5, as confirmed against a wide range of receptors and enzymes, including the hERG ion channel (50% inhibitory concentration, >10 microM), indicating potential for an excellent clinical safety profile.","Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16251317/),μM,10,168006,DB04835,Maraviroc
<,23364475,C(trough),"In three subjects, maraviroc C(trough) and C(avg) were <25 and <75 ng/mL, respectively (C(avg), 68 ng/mL and C(trough), 14 and 21 ng/mL).","Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23364475/),[ng] / [ml],25,168477,DB04835,Maraviroc
<,23364475,C(avg),"In three subjects, maraviroc C(trough) and C(avg) were <25 and <75 ng/mL, respectively (C(avg), 68 ng/mL and C(trough), 14 and 21 ng/mL).","Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23364475/),[ng] / [ml],25,168478,DB04835,Maraviroc
<,23364475,C(avg),"In three subjects, maraviroc C(trough) and C(avg) were <25 and <75 ng/mL, respectively (C(avg), 68 ng/mL and C(trough), 14 and 21 ng/mL).","Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23364475/),[ng] / [ml],75,168479,DB04835,Maraviroc
,23364475,C(avg),"In three subjects, maraviroc C(trough) and C(avg) were <25 and <75 ng/mL, respectively (C(avg), 68 ng/mL and C(trough), 14 and 21 ng/mL).","Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23364475/),[ng] / [ml],68,168480,DB04835,Maraviroc
,23364475,C(trough),"In three subjects, maraviroc C(trough) and C(avg) were <25 and <75 ng/mL, respectively (C(avg), 68 ng/mL and C(trough), 14 and 21 ng/mL).","Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23364475/),[ng] / [ml],14,168481,DB04835,Maraviroc
,23364475,C(trough),"In three subjects, maraviroc C(trough) and C(avg) were <25 and <75 ng/mL, respectively (C(avg), 68 ng/mL and C(trough), 14 and 21 ng/mL).","Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23364475/),[ng] / [ml],21,168482,DB04835,Maraviroc
,23364475,total maravir,"Although not statistically significant, a trend was observed towards lower maraviroc, darunavir and ritonavir concentrations in period 2 versus period 1; total maraviroc exposure was 3579 ng· h/mL (95% CI: 2983-4294) and 2996 ng· h/mL (95% CI: 2374-3782) in periods 1 and 2, respectively, and the GM ratio was 0.84 (95% CI: 0.67-1.05).","Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23364475/),[h·ng] / [ml],3579,168483,DB04835,Maraviroc
,23364475,total maravir,"Although not statistically significant, a trend was observed towards lower maraviroc, darunavir and ritonavir concentrations in period 2 versus period 1; total maraviroc exposure was 3579 ng· h/mL (95% CI: 2983-4294) and 2996 ng· h/mL (95% CI: 2374-3782) in periods 1 and 2, respectively, and the GM ratio was 0.84 (95% CI: 0.67-1.05).","Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23364475/),[h·ng] / [ml],2996,168484,DB04835,Maraviroc
,23364475,exposure,"Although not statistically significant, a trend was observed towards lower maraviroc, darunavir and ritonavir concentrations in period 2 versus period 1; total maraviroc exposure was 3579 ng· h/mL (95% CI: 2983-4294) and 2996 ng· h/mL (95% CI: 2374-3782) in periods 1 and 2, respectively, and the GM ratio was 0.84 (95% CI: 0.67-1.05).","Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23364475/),[h·ng] / [ml],3579,168485,DB04835,Maraviroc
,23364475,exposure,"Although not statistically significant, a trend was observed towards lower maraviroc, darunavir and ritonavir concentrations in period 2 versus period 1; total maraviroc exposure was 3579 ng· h/mL (95% CI: 2983-4294) and 2996 ng· h/mL (95% CI: 2374-3782) in periods 1 and 2, respectively, and the GM ratio was 0.84 (95% CI: 0.67-1.05).","Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23364475/),[h·ng] / [ml],2996,168486,DB04835,Maraviroc
,18647303,K(m),Maraviroc was metabolized to its N-dealkylated product via a single CYP enzyme characterized by a K(m) of 21 microM and V(max) of 0.45 pmol pmol(-1) min(-1) in human liver microsomes and was inhibited by ketoconazole (CYP3A4 inhibitor).,Maraviroc: in vitro assessment of drug-drug interaction potential. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18647303/),μM,21,169385,DB04835,Maraviroc
,18647303,V(max),Maraviroc was metabolized to its N-dealkylated product via a single CYP enzyme characterized by a K(m) of 21 microM and V(max) of 0.45 pmol pmol(-1) min(-1) in human liver microsomes and was inhibited by ketoconazole (CYP3A4 inhibitor).,Maraviroc: in vitro assessment of drug-drug interaction potential. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18647303/),[pM] / [min·pmol],0.45,169386,DB04835,Maraviroc
,18647303,K(m),"Using recombinant CYP3A4, N-dealkylation was characterized by a K(m) of 13 microM and a V(max) of 3 pmol pmol(-1) CYP min(-1).",Maraviroc: in vitro assessment of drug-drug interaction potential. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18647303/),μM,13,169387,DB04835,Maraviroc
,18647303,V(max),"Using recombinant CYP3A4, N-dealkylation was characterized by a K(m) of 13 microM and a V(max) of 3 pmol pmol(-1) CYP min(-1).",Maraviroc: in vitro assessment of drug-drug interaction potential. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18647303/),[cyp·pM] / [min·pmol],3,169388,DB04835,Maraviroc
below,26202768,trough concentration (Ctrough),"Only 1 patient showed a trough concentration (Ctrough) below the suggested target of 50 ng/mL, both during pregnancy and post partum.",Maraviroc Pharmacokinetics in HIV-1-Infected Pregnant Women. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26202768/),[ng] / [ml],50,174677,DB04835,Maraviroc
,27498124,area under the concentration-time curve from 0 to 12 hours,Mean (± SD) area under the concentration-time curve from 0 to 12 hours was 4805 ± 3265 hour * ng/mL on day 0 and 5917 ± 4048 hour * ng/mL on day +10.,A Pharmacokinetic and Pharmacodynamic Study of Maraviroc as Acute Graft-versus-Host Disease Prophylaxis in Pediatric Allogeneic Stem Cell Transplant Recipients with Nonmalignant Diagnoses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27498124/),[h·ng] / [ml],4805,177950,DB04835,Maraviroc
,27498124,area under the concentration-time curve from 0 to 12 hours,Mean (± SD) area under the concentration-time curve from 0 to 12 hours was 4805 ± 3265 hour * ng/mL on day 0 and 5917 ± 4048 hour * ng/mL on day +10.,A Pharmacokinetic and Pharmacodynamic Study of Maraviroc as Acute Graft-versus-Host Disease Prophylaxis in Pediatric Allogeneic Stem Cell Transplant Recipients with Nonmalignant Diagnoses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27498124/),[h·ng] / [ml],5917,177951,DB04835,Maraviroc
,23835512,area under the plasma concentration-time curve for the dosing interval (AUCtau),"With SQV/r, geometric mean steady-state maraviroc area under the plasma concentration-time curve for the dosing interval (AUCtau) was 5,341 (coefficient of variation [CV], 27%), 8,119 (35%), and 6,193 (27%) h•ng/mL, in normal function, mild, and moderate impairment groups, respectively.","Pharmacokinetics, safety, and tolerability of maraviroc in HIV-negative subjects with impaired renal function. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23835512/),[h·ng] / [ml],"5,341",179020,DB04835,Maraviroc
,23835512,area under the plasma concentration-time curve for the dosing interval (AUCtau),"With SQV/r, geometric mean steady-state maraviroc area under the plasma concentration-time curve for the dosing interval (AUCtau) was 5,341 (coefficient of variation [CV], 27%), 8,119 (35%), and 6,193 (27%) h•ng/mL, in normal function, mild, and moderate impairment groups, respectively.","Pharmacokinetics, safety, and tolerability of maraviroc in HIV-negative subjects with impaired renal function. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23835512/),[h·ng] / [ml],"8,119",179021,DB04835,Maraviroc
,23835512,area under the plasma concentration-time curve for the dosing interval (AUCtau),"With SQV/r, geometric mean steady-state maraviroc area under the plasma concentration-time curve for the dosing interval (AUCtau) was 5,341 (coefficient of variation [CV], 27%), 8,119 (35%), and 6,193 (27%) h•ng/mL, in normal function, mild, and moderate impairment groups, respectively.","Pharmacokinetics, safety, and tolerability of maraviroc in HIV-negative subjects with impaired renal function. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23835512/),[h·ng] / [ml],"6,193",179022,DB04835,Maraviroc
,20696881,Maximum plasma maraviroc concentrations,"Maximum plasma maraviroc concentrations were found at delivery (2-h-postintrapartum dose) in both the mothers and infants, with median concentrations of 974 ng/ml (range, 86 to 2,830 ng/ml) and 22 ng/ml (range, 4 to 99 ng/ml), respectively.",Maternal-fetal pharmacokinetics and dynamics of a single intrapartum dose of maraviroc in rhesus macaques. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20696881/),[ng] / [ml],974,179166,DB04835,Maraviroc
,20696881,Maximum plasma maraviroc concentrations,"Maximum plasma maraviroc concentrations were found at delivery (2-h-postintrapartum dose) in both the mothers and infants, with median concentrations of 974 ng/ml (range, 86 to 2,830 ng/ml) and 22 ng/ml (range, 4 to 99 ng/ml), respectively.",Maternal-fetal pharmacokinetics and dynamics of a single intrapartum dose of maraviroc in rhesus macaques. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20696881/),[ng] / [ml],22,179167,DB04835,Maraviroc
,20696881,concentrations,"Maximum plasma maraviroc concentrations were found at delivery (2-h-postintrapartum dose) in both the mothers and infants, with median concentrations of 974 ng/ml (range, 86 to 2,830 ng/ml) and 22 ng/ml (range, 4 to 99 ng/ml), respectively.",Maternal-fetal pharmacokinetics and dynamics of a single intrapartum dose of maraviroc in rhesus macaques. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20696881/),[ng] / [ml],974,179168,DB04835,Maraviroc
,20696881,concentrations,"Maximum plasma maraviroc concentrations were found at delivery (2-h-postintrapartum dose) in both the mothers and infants, with median concentrations of 974 ng/ml (range, 86 to 2,830 ng/ml) and 22 ng/ml (range, 4 to 99 ng/ml), respectively.",Maternal-fetal pharmacokinetics and dynamics of a single intrapartum dose of maraviroc in rhesus macaques. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20696881/),[ng] / [ml],22,179169,DB04835,Maraviroc
,20696881,area under the concentration-time curve (AUC) ratio,"The median fetal-maternal area under the concentration-time curve (AUC) ratio was 0.009 (range, 0.000 to 0.015).",Maternal-fetal pharmacokinetics and dynamics of a single intrapartum dose of maraviroc in rhesus macaques. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20696881/),,0.009,179170,DB04835,Maraviroc
,27435752,Racc,"Finally, the model was refined to incorporate the fractional contribution of enzymes, including CYP2B6, propagating autoinduction into the model (Racc 1.7 vs. 1.7 observed).",Towards a Best Practice Approach in PBPK Modeling: Case Example of Developing a Unified Efavirenz Model Accounting for Induction of CYPs 3A4 and 2B6. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27435752/),,1.7,183894,DB04835,Maraviroc
,23740994,concentrations,"Median MVC concentrations in rectal tissues at 24 h (1,404 ng/g) were 30 and 10 times those achieved in vaginal or lymphoid tissues, respectively.",Lack of prophylactic efficacy of oral maraviroc in macaques despite high drug concentrations in rectal tissues. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23740994/),[ng] / [g],"1,404",191572,DB04835,Maraviroc
,23740994,half-life,The half-life of CCR5-bound MVC in PBMCs was 2.6 days.,Lack of prophylactic efficacy of oral maraviroc in macaques despite high drug concentrations in rectal tissues. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23740994/),d,2.6,191573,DB04835,Maraviroc
,23797691,VL,"Baseline median (Q1, Q3) CD4 count and VL were 455 (299, 607) cells per cubic millimeter and 4.62 (4.18, 4.80) log10 copies per milliliter, respectively.","Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23797691/),,4,202800,DB04835,Maraviroc
,23797691,trough concentrations,"Individual maraviroc trough concentrations collected between 20 and 28 hours post dose (n = 59) was 13.7 to 130 ng/mL (Q1, 23.4 ng/mL; Q3, 46.5 ng/mL), and modeled steady-state concentration was 128 ng/mL.","Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23797691/),[ng] / [ml],13.7 to 130,202801,DB04835,Maraviroc
,23797691,Q1,"Individual maraviroc trough concentrations collected between 20 and 28 hours post dose (n = 59) was 13.7 to 130 ng/mL (Q1, 23.4 ng/mL; Q3, 46.5 ng/mL), and modeled steady-state concentration was 128 ng/mL.","Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23797691/),[ng] / [ml],23.4,202802,DB04835,Maraviroc
,23797691,Q3,"Individual maraviroc trough concentrations collected between 20 and 28 hours post dose (n = 59) was 13.7 to 130 ng/mL (Q1, 23.4 ng/mL; Q3, 46.5 ng/mL), and modeled steady-state concentration was 128 ng/mL.","Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23797691/),[ng] / [ml],46.5,202803,DB04835,Maraviroc
,23797691,steady-state concentration,"Individual maraviroc trough concentrations collected between 20 and 28 hours post dose (n = 59) was 13.7 to 130 ng/mL (Q1, 23.4 ng/mL; Q3, 46.5 ng/mL), and modeled steady-state concentration was 128 ng/mL.","Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23797691/),[ng] / [ml],128,202804,DB04835,Maraviroc
,19546811,protein binding,"On day 7, maraviroc CVF protein binding was 7.6% and the VT AUCtau was 1.9-fold higher than BP.",Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19546811/),%,7.6,223782,DB04835,Maraviroc
,24861522,trough concentrations (Ctrough),"240 trough samples were available (3-7 per patient); etravirine trough concentrations (Ctrough) and weighted genotypic inhibitory quotients (wgIQ) were 426ng/mL (266-763) and 408ng/mL/mutation (227-663), respectively.",Etravirine plasma exposure is associated with virological efficacy in treatment-experienced HIV-positive patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24861522/),[ng] / [ml],426,240762,DB04835,Maraviroc
,24861522,inhibitory quotients (wgIQ),"240 trough samples were available (3-7 per patient); etravirine trough concentrations (Ctrough) and weighted genotypic inhibitory quotients (wgIQ) were 426ng/mL (266-763) and 408ng/mL/mutation (227-663), respectively.",Etravirine plasma exposure is associated with virological efficacy in treatment-experienced HIV-positive patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24861522/),[ng] / [ml·mutation],408,240763,DB04835,Maraviroc
>,20078612,AUC(tau),"In all subjects, maraviroc average concentrations (AUC(tau) divided by 12) were >100 ng ml(-1), the threshold value below which there is an increased risk of virological failure.",Assessment of the pharmacokinetics of co-administered maraviroc and raltegravir. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20078612/),[ng] / [ml],100,244887,DB04835,Maraviroc
∼5,30862625,high-affinity,"MVC showed significant active uptake and biliary excretion in sandwich-cultured human hepatocytes, and biphasic organic anion transporting polypeptide (OATP)1B1-mediated uptake kinetics in transfected cells (high-affinity K m ∼5 µM).","Mechanistic Evaluation of the Complex Drug-Drug Interactions of Maraviroc: Contribution of Cytochrome P450 3A, P-Glycoprotein and Organic Anion Transporting Polypeptide 1B1. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30862625/),,µ,270037,DB04835,Maraviroc
∼5,30862625,K m,"MVC showed significant active uptake and biliary excretion in sandwich-cultured human hepatocytes, and biphasic organic anion transporting polypeptide (OATP)1B1-mediated uptake kinetics in transfected cells (high-affinity K m ∼5 µM).","Mechanistic Evaluation of the Complex Drug-Drug Interactions of Maraviroc: Contribution of Cytochrome P450 3A, P-Glycoprotein and Organic Anion Transporting Polypeptide 1B1. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30862625/),,µ,270038,DB04835,Maraviroc
,30862625,"inactivation constant, K I","TVR inhibited OATP1B1-mediated MVC transport in vitro, and also exhibited CYP3A time-dependent inhibition in human hepatocytes (inactivation constant, K I = 2.24 µM, and maximum inactivation rate constant, k inact = 0.0112 minute-1).","Mechanistic Evaluation of the Complex Drug-Drug Interactions of Maraviroc: Contribution of Cytochrome P450 3A, P-Glycoprotein and Organic Anion Transporting Polypeptide 1B1. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30862625/),μM,2.24,270039,DB04835,Maraviroc
,30862625,"maximum inactivation rate constant, k inact","TVR inhibited OATP1B1-mediated MVC transport in vitro, and also exhibited CYP3A time-dependent inhibition in human hepatocytes (inactivation constant, K I = 2.24 µM, and maximum inactivation rate constant, k inact = 0.0112 minute-1).","Mechanistic Evaluation of the Complex Drug-Drug Interactions of Maraviroc: Contribution of Cytochrome P450 3A, P-Glycoprotein and Organic Anion Transporting Polypeptide 1B1. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30862625/),1/[min],0.0112,270040,DB04835,Maraviroc
,18333866,renal clearance,Mean values for renal clearance ranged from 8.2 l h(-1) (cohort 1) to 13.2 l h(-1) (cohort 4).,A novel probe drug interaction study to investigate the effect of selected antiretroviral combinations on the pharmacokinetics of a single oral dose of maraviroc in HIV-positive subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18333866/),[l] / [h],8.2,273885,DB04835,Maraviroc
,18333866,renal clearance,Mean values for renal clearance ranged from 8.2 l h(-1) (cohort 1) to 13.2 l h(-1) (cohort 4).,A novel probe drug interaction study to investigate the effect of selected antiretroviral combinations on the pharmacokinetics of a single oral dose of maraviroc in HIV-positive subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18333866/),[l] / [h],13.2,273886,DB04835,Maraviroc
